ACAD
30.43
+0.34
+1.13%
AEMD
2.06
+0.01
+0.49%
APRI
1.08
-0.02
-1.82%
ARNA
24.05
+0.47
+1.99%
ATEC
1.725
-0.065
-3.631%
CNAT
6.04
0.00
0.00%
CRXM
0.169
0.00
0.00%
CYTX
1.11
-0.01
-0.89%
DXCM
69.52
-0.49
-0.70%
GNMK
12.05
-0.21
-1.71%
HALO
13.53
+0.27
+2.04%
ILMN
172.75
+0.78
+0.45%
INNV
0.116
-0.005
-4.132%
INO
6.01
0.00
0.00%
ISCO
1.23
-0.1
-7.52%
ISIS
57.56
0.00
0.00%
LGND
123.05
+2.36
+1.96%
LPTN
2.93
-2.93
-100.00%
MBVX
0.96
+0.03
+3.23%
MEIP
3.02
-0.05
-1.63%
MNOV
5.43
+0.12
+2.26%
MRTX
4.9
+0.25
+5.38%
MSTX
0.131
-0.007
-5.278%
NBIX
47.07
-0.72
-1.51%
NUVA
79.92
-1.19
-1.47%
ONCS
1.08
-0.04
-3.57%
ONVO
2.37
+0.05
+2.16%
OREX
2.47
-0.13
-5.00%
OTIC
18.9
+0.15
+0.80%
QDEL
37.71
-0.02
-0.05%
RCPT
231.96
0.00
0.00%
RGLS
0.98
+0.1
+11.36%
RMD
77
-1.03
-1.32%
SCIE
0
0.00
-14.2857%
SPHS
2.07
0.00
0.00%
SRNE
2.05
0.00
0.00%
TROV
0.96
-0.03
-3.03%
VICL
2.66
+0.01
+0.37%
VOLC
18
0.00
0.00%
ZGNX
13.4
-0.2
-1.47%
ACAD
30.43
+0.34
+1.13%
AEMD
2.06
+0.01
+0.49%
APRI
1.08
-0.02
-1.82%
ARNA
24.05
+0.47
+1.99%
ATEC
1.725
-0.065
-3.631%
CNAT
6.04
0.00
0.00%
CRXM
0.169
0.00
0.00%
CYTX
1.11
-0.01
-0.89%
DXCM
69.52
-0.49
-0.70%
GNMK
12.05
-0.21
-1.71%
HALO
13.53
+0.27
+2.04%
ILMN
172.75
+0.78
+0.45%
INNV
0.116
-0.005
-4.132%
INO
6.01
0.00
0.00%
ISCO
1.23
-0.1
-7.52%
ISIS
57.56
0.00
0.00%
LGND
123.05
+2.36
+1.96%
LPTN
2.93
-2.93
-100.00%
MBVX
0.96
+0.03
+3.23%
MEIP
3.02
-0.05
-1.63%
MNOV
5.43
+0.12
+2.26%
MRTX
4.9
+0.25
+5.38%
MSTX
0.131
-0.007
-5.278%
NBIX
47.07
-0.72
-1.51%
NUVA
79.92
-1.19
-1.47%
ONCS
1.08
-0.04
-3.57%
ONVO
2.37
+0.05
+2.16%
OREX
2.47
-0.13
-5.00%
OTIC
18.9
+0.15
+0.80%
QDEL
37.71
-0.02
-0.05%
RCPT
231.96
0.00
0.00%
RGLS
0.98
+0.1
+11.36%
RMD
77
-1.03
-1.32%
SCIE
0
0.00
-14.2857%
SPHS
2.07
0.00
0.00%
SRNE
2.05
0.00
0.00%
TROV
0.96
-0.03
-3.03%
VICL
2.66
+0.01
+0.37%
VOLC
18
0.00
0.00%
ZGNX
13.4
-0.2
-1.47%
Home » Archive by Category

News

San Diego biotech news from BioSpace, Xconomy, PR Newswire, Marketwired and other sources, click on headlines to read the full story.

The Scientist and the Student: Thoughts on Lessons Learned From a Mentor

December 24, 2015 – 1:00 am

What is a key relationship or turning point that helped you get to where you are today? This is a great question. I suspect because it comes up so often in interviews, we tend to underplay the…

[[Click headline to continue reading.]]

The Scientist and the Student: Thoughts on Lessons Learned From a Mentor

December 24, 2015 – 1:00 am

What is a key relationship or turning point that helped you get to where you are today? This is a great question. I suspect because it comes up so often in interviews, we tend to underplay the…

[[Click headline to continue reading.]]

The Scientist and the Student: Thoughts on Lessons Learned From a Mentor

December 24, 2015 – 1:00 am

What is a key relationship or turning point that helped you get to where you are today? This is a great question. I suspect because it comes up so often in interviews, we tend to underplay the…

[[Click headline to continue reading.]]

VistaGen Secures Exclusive Worldwide Commercial Rights to Three Proprietary Stem Cell Technologies from University Health Network

December 23, 2015 – 5:53 am

New Licenses Expand Core Drug Rescue Programs and Collaborative Regenerative Medicine Opportunities Related to Heart Disease, Liver Disease and Osteoarthritis

SOUTH SAN FRANCISCO, Calif., Dec. 23, 2015 /PRNewswire/ — VistaGen Therapeutics, Inc. (OTCQB: VSTA), a clinical-stage biopharmaceutical company committed to developing and commercializing novel medicines to treat depression, cancer and diseases and disorders involving the central nervous system, today announced that it has secured exclusive worldwide commercial rights to three patent-pending stem cell technologies from University Health Network (UHN), Canada’s largest research hospital. The newly licensed technologies were discovered and developed by distinguished UHN researcher, Dr. Gordon Keller, Director of UHN’s McEwen Centre for Regenerative Medicine (McEwen Centre), one of the world’s leading centers for stem cell and regenerative medicine research, and relate to the development of stem cells into heart, liver and cartilage cells for multiple potential commercial applications, including drug rescue and regenerative therapies for heart disease, liver disease and osteoarthritis. VistaGen now holds a total of five licenses to stem cell technologies developed in collaboration with UHN, the McEwen Centre and Dr. Keller.

“We are pleased to have the opportunity to further expand our relationship with the world renowned UHN and McEwen Centre. These latest licensing agreements will be instrumental to our core drug rescue programs and lay a solid foundation to explore collaborative opportunities to advance Dr. Keller’s ground-breaking discoveries beyond the lab and towards the clinic,” stated Shawn Singh, Chief Executive Officer of VistaGen. 

Today’s announced agreements cover the following:

  • Methods and compositions for generating epicardium cells from pluripotent stem cells, an achievement that no other medical research lab in the world has yet been able to accomplish. Epicardium cells are essential for proper development of the heart, and play an important role in cardiac recovery during disease.
  • Methods for generating hepatocytes (a major cell-type in the liver) and cholangiocytes (cells which line the bile ducts) from pluripotent stem cells, which offer new and improved approaches for evaluating the liver safety of drug candidates, as well as cell therapy opportunities for liver failure and/or diseases involving the bile system of the liver, including cystic fibrosis (CF) liver disease, the third most frequent cause of death in CF.
  • Methods and compositions for generating chondrocyte lineage cells which produce either articular (cartilage) or growth plate (bone-forming) chondrocytes important in development of future regenerative therapies to treat bone related injuries and osteoarthritis.

About VistaGen Therapeutics

VistaGen Therapeutics, Inc. (OTCQB: VSTA) is a clinical-stage biopharmaceutical company committed to developing and commercializing novel medicines to treat depression, cancer and diseases and disorders involving the central nervous system (CNS). VistaGen’s AV-101 is a new generation orally available NMDAR GlyB antagonist in Phase 2 clinical development for the adjunctive treatment of Major Depressive Disorder in patients with an inadequate response to standard antidepressant therapies. Based on preclinical studies, AV-101 may also have potential as a treatment for other CNS-related conditions, including chronic neuropathic pain and epilepsy, as well as neurodegenerative diseases such as Parkinson’s disease and Huntington’s disease. VistaGen is among the first generation of companies using pluripotent stem cell technology for potential commercial applications focused on producing proprietary new chemical entities (NCEs) through drug rescue and regenerative therapies for diseases and conditions related to blood, cartilage, heart and liver cells. For additional information, please visit www.VistaGen.com.

Cautionary Statement Regarding Forward-Looking Statements

The statements in this press release that are not historical facts may constitute forward-looking statements that are based on current expectations and are subject to risks and uncertainties that could cause actual future results to differ materially from those expressed or implied by such statements. Those risks and uncertainties include, but are not limited to, risks related to the VistaGen’s successful Phase 2 clinical development of AV-101 in MDD, its drug rescue programs, protection of its intellectual property, and the availability of substantial additional capital to support its operations, including the foregoing activities. These and other risks and uncertainties are identified and described in more detail in VistaGen’s filings with the Securities and Exchange Commission (SEC). These filings are available on the SEC’s website at www.sec.gov. VistaGen undertakes no obligation to publicly update or revise any forward-looking statements.

 

 

 

SOURCE VistaGen Therapeutics, Inc.

Amid Neuroscience Renaissance, BlackThorn Quietly Builds a Business

December 23, 2015 – 5:26 am

The past year has seen several new biotech companies announce ambitious goals of tackling neurological disease, a vast, complex, and frustrating region of biomedicine. The academic side of the field…

[[Click headline to continue reading.]]

Amid Neuroscience Renaissance, BlackThorn Quietly Builds a Business

December 23, 2015 – 5:26 am

The past year has seen several new biotech companies announce ambitious goals of tackling neurological disease, a vast, complex, and frustrating region of biomedicine. The academic side of the field…

[[Click headline to continue reading.]]

Amid Neuroscience Renaissance, BlackThorn Quietly Builds a Business

December 23, 2015 – 5:26 am

The past year has seen several new biotech companies announce ambitious goals of tackling neurological disease, a vast, complex, and frustrating region of biomedicine. The academic side of the field…

[[Click headline to continue reading.]]

Amid Neuroscience Renaissance, BlackThorn Quietly Builds a Business

December 23, 2015 – 5:26 am

The past year has seen several new biotech companies announce ambitious goals of tackling neurological disease, a vast, complex, and frustrating region of biomedicine. The academic side of the field…

[[Click headline to continue reading.]]

Biotech Showcase(TM) 2016 will be “home base” for investment community in San Francisco in January

December 22, 2015 – 9:12 am

CARLSBAD, Calif. and NEW YORK and SAN FRANCISCO, Dec. 22, 2015 /PRNewswire/ — The eighth annual Biotech Showcase™ investor and networking conference will be held in San Francisco during the healthcare industry’s busiest week of the year, January 11–13, 2016.

The event acts as home base for innovative mid-small cap and private life sciences companies and the public, private and strategic investors eager to meet with them. Over 300 innovative company presentations will take place during the three-day event.

“Biotech Showcase is a good opportunity not just to network and meet new people, but also to hear what young biotechs are doing, to gauge our peers’ interactions and to tell everyone about AstraZeneca’s recent deals and direction. It’s an opportunity to discuss challenges and where companies are heading, as well as the competitive landscape,” said Shaun Grady, VP, business development operations, AstraZeneca.

Monday’s lunch plenary, “The great pricing debate: Navigating through an industry sea change,” will address pricing issues that have the fragmented the biopharmaceutical industry. The plenary will be moderated by Mike Griffith – Executive VP Commercial Division, inVentiv Health, with panelists Ron Cohen – CEO, Acorda Therapeutics and Chairman, Biotechnology Industry Organization (BIO), and Beth L. Roberts – Partner, Hogan Lovells.

Tuesday’s lunch plenary, “State of the industry: It’s different this time,” will be moderated by Ben Bonifant – Founder and Partner, Triangle Insights Group, with panelists Philippe Lopes-Fernandes – Senior VP, Head, Global Licensing and Business Development, Merck KGaA, Darmstadt, Germany; Diego Miralles – Head, Johnson & Johnson Innovation; and Dennis Purcell – Founder and Senior Advisor, Aisling Capital.

Wednesday’s lunch plenary is entitled “Bubble trouble? Have the biotech bulls had their run?” moderated by Eric W. Blanchard – Partner, Covington & Burling LLP, with panelists Asthika Goonewardene – Senior Biotechnology Analyst, Bloomberg Intelligence; Art Pappas – Managing Partner, Pappas Ventures; and Alex Zisson – Partner, Thomas McNerney & Partners.

In addition to the annual workshop “The Life Sciences Report 2016 small-cap watchlist,” on Tuesday, there will be a “Medtech Showcase State of the Industry Report” during Medtech Showcase on January 12 featuring panelists from ICON, AdvaMed, Cohera Medical, and MDIC. There will also be a Digital Health Showcase State of the Industry Report entitled “At the intersection of technology and medicine” during Digital Health Showcase on January 13 moderated by Yarmela Pavlovic – Partner, Hogan Lovells, and featuring panelists from GE Healthcare Life Care, PureTech and WellDoc.

Biotech Showcase is produced by Demy-Colton Life Science Advisors and EBD Group. Both organizations have a long history of producing high quality programs that support the biotechnology and broader life sciences industry.

To register or for more information go to the Biotech Showcase 2016 website.

Follow Biotech Showcase 2016 on Twitter: @EBDGroup (hashtag: #BTS16).

Online Press Kit service for Biotech Showcase 2016 is available from PR Newswire to enhance your public relations efforts.

About  EBD Group

EBD Group is the leading partnering firm for the global life science industry. Since 1993, biotech, pharma and medical device companies have leveraged EBD Group’s partnering conferences, technology and services to identify business opportunities and develop strategic relationships essential to their success.

EBD Group’s conferences include:

For more information please visit www.ebdgroup.com.

About Demy-Colton Life Science Advisors

Demy-Colton Life Science Advisors is focused exclusively on facilitating the growth of the life science industry. Demy-Colton has developed a number of high-value added conferences to address the business and development needs of the biotechnology industry; it provides partnering services and it has helped launch a unique investor website and newsletter.

Demy-Colton’s conferences include:

Demy-Colton’s online partnering system, Networking2™, supports Demy-Colton’s events and facilitates investor and venture meetings for the pharma industry and partnering for other organizations.

For more information please visit www.demy-colton.com.

 

SOURCE EBD Group

Novoron Bioscience Awarded NIH Grant to Evaluate New Treatments for Multiple Sclerosis

December 22, 2015 – 7:00 am

Goal of research is to test whether inhibiting Rho kinase via receptor-associated protein will promote remyelination

SAN DIEGO, Dec. 22, 2015 /PRNewswire/ — Novoron Bioscience, Inc., a private biotech company dedicated to developing new therapeutics for disorders of the central nervous system, today announced that the company has been awarded a National Institutes of Health (NIH) grant under the Small Business Innovation Research (SBIR) Program.  The NIH grant totaling $680,000 will fund preclinical studies to evaluate a novel therapeutic approach for promoting remyelination in multiple sclerosis (MS) for two years. Novoron has received six NIH grants, totaling more than $1.2 million, to test new therapeutic approaches in neurological disorders, including MS, stroke, and spinal cord injury.  

“These NIH grants are invaluable in helping us advance our novel therapeutic approaches, addressing fundamental limitations in the treatment of disorders of the central nervous system such as multiple sclerosis, spinal cord injury and optic neuropathies,” said Travis Stiles, Ph.D., President and CEO of Novoron Bioscience.  “We look forward to the opportunity to continue to extend our unique technological approach to CNS disease and assess our capacity to promote remyelination and preserve neuronal viability in multiple sclerosis.”

MS is an autoimmune disease of the central nervous system where the immune system attacks the protective coating of nerves in the brain and spinal cord, known as myelin. This process is known as demyelination, which is irreversible in MS, and the primary cause of disability and death in this disease. Without proper myelin protection, nerves cannot efficiently transmit information, and will often die, leading to loss of critical human functions such as vision, movement, and speech.  With more than 2.3 million people globally fighting the disease, MS is one of the most common diseases of the brain and spinal cord and is the most common neurological condition affecting young people.

“Today’s approved therapies are aimed solely at dampening the autoimmune attack on myelin, but there are currently no approved treatments to repair damage after an attack has occurred,” explained Dr. Stiles. “Our approach shows substantial promise towards repairing this damage, a process known as remyelination, which not only protects neurons from further damage, but can lead to recovery of cell function and prevention of death.”

Under normal conditions, when the brain faces an insult such as trauma to the head or environmental toxicity, oligodendrocytes, the cells responsible for creating the myelin coating, can die and leave an unattended myelin sheath to degrade and fall apart. Under such circumstances, the body has a reserve of cells known as oligodendrocyte precursor cells (OPCs), which readily infiltrate the area of damage and take the place of lost oligodendrocytes, synthesizing new myelin and repairing the damage. However, in MS, persistent myelin debris coupled with the inflammatory consequences of immune infiltration inhibits the ability of OPCs to create new myelin. This is caused by an unwanted activation of a molecule called RhoA, which is the target of Novoron’s therapeutic approach.  

“Rho and Rho-kinase are well considered targets for multiple sclerosis, but are difficult to effectively inhibit therapeutically in the brain. Novoron’s technological foundation relies on our unique approach to targeting RhoA in a fashion that is amenable to disorders of the brain and spinal cord,” concluded Dr. Stiles.

Novoron’s lead compound, NOVO-117, acts on a previously unknown mediator of RhoA activation in CNS disease, LRP1 (low density lipoprotein-related protein 1). This grant will provide the necessary proof of concept to validate further pre-clinical development of NOVO-117 as an MS therapy. 

The grant is supported by the National Institute of Neurological Disorders and Stroke (NINDS) at the NIH under Award Number R43NS092182. The content of this press release is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health.

About Novoron Bioscience

Novoron Bioscience, Inc. is a private biotech company developing novel therapeutic approaches to address disorders of the central nervous system. The company has made proprietary scientific discoveries in nerve regeneration and is advancing a pipeline of biologic therapeutics for spinal cord injury, multiple sclerosis and glaucoma.  Novoron is headquartered in San Diego and is part of the JLABS innovation community.

For more information, please visit: www.novoron.com and connect with us on Twitter @novoronbio.

 

SOURCE Novoron Bioscience